Neurones
Neurones S.A. provides infrastructure, application, and consulting services in France. The company offers cloud, infrastructure management, DevOps, cybersecurity, user support, IT service management, information system governance, and automation services. It also provides digital, UX/UI, agile, devOps, mobility, and data; SAP integration and outsourcing content management, business process manage… Read more
Neurones (NRO) - Net Assets
Latest net assets as of June 2025: €431.66 Million EUR
Based on the latest financial reports, Neurones (NRO) has net assets worth €431.66 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€717.70 Million) and total liabilities (€286.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €431.66 Million |
| % of Total Assets | 60.14% |
| Annual Growth Rate | 10.17% |
| 5-Year Change | 21.49% |
| 10-Year Change | 102.17% |
| Growth Volatility | 3.19 |
Neurones - Net Assets Trend (2000–2024)
This chart illustrates how Neurones's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Neurones (2000–2024)
The table below shows the annual net assets of Neurones from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €436.17 Million | +6.93% |
| 2023-12-31 | €407.91 Million | +8.61% |
| 2022-12-31 | €375.58 Million | +6.42% |
| 2021-12-31 | €352.92 Million | -1.70% |
| 2020-12-31 | €359.02 Million | +9.69% |
| 2019-12-31 | €327.32 Million | +10.63% |
| 2018-12-31 | €295.88 Million | +10.38% |
| 2017-12-31 | €268.05 Million | +12.41% |
| 2016-12-31 | €238.46 Million | +10.52% |
| 2015-12-31 | €215.75 Million | +9.59% |
| 2014-12-31 | €196.88 Million | +12.37% |
| 2013-12-31 | €175.21 Million | +12.73% |
| 2012-12-31 | €155.42 Million | +11.71% |
| 2011-12-31 | €139.13 Million | +14.67% |
| 2010-12-31 | €121.33 Million | +12.05% |
| 2009-12-31 | €108.28 Million | +11.73% |
| 2008-12-31 | €96.91 Million | +12.83% |
| 2007-12-31 | €85.89 Million | +12.26% |
| 2006-12-31 | €76.51 Million | +8.30% |
| 2005-12-31 | €70.65 Million | +9.20% |
| 2004-12-31 | €64.70 Million | +9.74% |
| 2003-12-31 | €58.96 Million | +8.96% |
| 2002-12-31 | €54.11 Million | +12.81% |
| 2001-12-31 | €47.97 Million | +12.52% |
| 2000-12-31 | €42.63 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neurones's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5255600000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €52.56 Million | 13.90% |
| Common Stock | €9.71 Million | 2.57% |
| Other Comprehensive Income | €299.76 Million | 79.28% |
| Other Components | €16.08 Million | 4.25% |
| Total Equity | €378.10 Million | 100.00% |
Neurones Competitors by Market Cap
The table below lists competitors of Neurones ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sichuan Golden Summit Group Joint Stock Co Ltd
SHG:600678
|
$431.97 Million |
|
NORTHRIM BA. DL-01
F:NRI
|
$432.03 Million |
|
Sunflower Pharmaceuticals Group Co Ltd
SHE:002737
|
$432.08 Million |
|
Gr. Sarantis S.A
PINK:SRTSF
|
$432.15 Million |
|
China Education Group Holdings Limited
PINK:CEGHF
|
$431.82 Million |
|
D I Corp
KO:003160
|
$431.82 Million |
|
Minda Corporation Limited
NSE:MINDACORP
|
$431.76 Million |
|
Mativ Holdings Inc.
NYSE:MATV
|
$431.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neurones's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 354,389,000 to 378,104,000, a change of 23,715,000 (6.7%).
- Net income of 52,500,000 contributed positively to equity growth.
- Dividend payments of 29,126,000 reduced retained earnings.
- Share repurchases of 28,000 reduced equity.
- Other comprehensive income increased equity by 35,427,000.
- Other factors decreased equity by 35,058,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €52.50 Million | +13.89% |
| Dividends Paid | €29.13 Million | -7.7% |
| Share Repurchases | €28.00K | -0.01% |
| Other Comprehensive Income | €35.43 Million | +9.37% |
| Other Changes | €-35.06 Million | -9.27% |
| Total Change | €- | 6.69% |
Book Value vs Market Value Analysis
This analysis compares Neurones's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.25x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 15.83x to 2.25x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | €2.20 | €34.90 | x |
| 2003-12-31 | €2.34 | €34.90 | x |
| 2004-12-31 | €2.62 | €34.90 | x |
| 2005-12-31 | €2.89 | €34.90 | x |
| 2006-12-31 | €2.97 | €34.90 | x |
| 2007-12-31 | €3.41 | €34.90 | x |
| 2008-12-31 | €3.83 | €34.90 | x |
| 2009-12-31 | €4.35 | €34.90 | x |
| 2010-12-31 | €4.82 | €34.90 | x |
| 2011-12-31 | €5.39 | €34.90 | x |
| 2012-12-31 | €6.00 | €34.90 | x |
| 2013-12-31 | €6.73 | €34.90 | x |
| 2014-12-31 | €7.45 | €34.90 | x |
| 2015-12-31 | €8.22 | €34.90 | x |
| 2016-12-31 | €8.95 | €34.90 | x |
| 2017-12-31 | €10.00 | €34.90 | x |
| 2018-12-31 | €10.99 | €34.90 | x |
| 2019-12-31 | €12.23 | €34.90 | x |
| 2020-12-31 | €13.29 | €34.90 | x |
| 2021-12-31 | €12.85 | €34.90 | x |
| 2022-12-31 | €13.61 | €34.90 | x |
| 2023-12-31 | €14.58 | €34.90 | x |
| 2024-12-31 | €15.53 | €34.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neurones utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.89%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.48%
- • Asset Turnover: 1.12x
- • Equity Multiplier: 1.92x
- Recent ROE (13.89%) is above the historical average (11.20%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 9.14% | 5.82% | 1.06x | 1.48x | €-361.10K |
| 2001 | 11.08% | 6.10% | 1.15x | 1.58x | €509.30K |
| 2002 | 11.53% | 6.43% | 1.17x | 1.53x | €790.80K |
| 2003 | 8.70% | 5.24% | 1.13x | 1.47x | €-725.60K |
| 2004 | 8.62% | 5.59% | 1.04x | 1.48x | €-871.50K |
| 2005 | 8.64% | 5.44% | 1.08x | 1.47x | €-935.30K |
| 2006 | 9.22% | 5.08% | 1.10x | 1.65x | €-560.90K |
| 2007 | 12.04% | 6.38% | 1.15x | 1.64x | €1.68 Million |
| 2008 | 14.21% | 6.85% | 1.14x | 1.81x | €3.85 Million |
| 2009 | 12.57% | 5.92% | 1.28x | 1.66x | €2.62 Million |
| 2010 | 13.08% | 6.24% | 1.26x | 1.66x | €3.52 Million |
| 2011 | 11.44% | 5.22% | 1.26x | 1.74x | €1.86 Million |
| 2012 | 10.30% | 4.71% | 1.26x | 1.73x | €427.00K |
| 2013 | 11.48% | 5.41% | 1.23x | 1.72x | €2.39 Million |
| 2014 | 11.36% | 5.77% | 1.17x | 1.69x | €2.45 Million |
| 2015 | 10.76% | 5.35% | 1.14x | 1.77x | €1.52 Million |
| 2016 | 11.61% | 5.64% | 1.16x | 1.78x | €3.50 Million |
| 2017 | 11.24% | 5.63% | 1.18x | 1.69x | €3.01 Million |
| 2018 | 9.73% | 5.30% | 1.09x | 1.68x | €-724.10K |
| 2019 | 10.36% | 6.04% | 1.00x | 1.72x | €1.08 Million |
| 2020 | 9.58% | 5.89% | 0.95x | 1.70x | €-1.34 Million |
| 2021 | 12.10% | 6.50% | 1.02x | 1.82x | €6.55 Million |
| 2022 | 13.38% | 6.65% | 1.08x | 1.86x | €11.18 Million |
| 2023 | 13.94% | 6.67% | 1.10x | 1.90x | €13.97 Million |
| 2024 | 13.89% | 6.48% | 1.12x | 1.92x | €14.69 Million |
Industry Comparison
This section compares Neurones's net assets metrics with peer companies in the Information Technology Services industry.
Industry Context
- Industry: Information Technology Services
- Average net assets among peers: $64,558,330
- Average return on equity (ROE) among peers: 14.72%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neurones (NRO) | €431.66 Million | 9.14% | 0.66x | $431.86 Million |
| Hitechpros (ALHIT) | $658.00K | 63.37% | 0.42x | $3.16 Million |
| IT Link (ALITL) | $28.43 Million | 14.18% | 1.14x | $11.65 Million |
| Keyrus SA (ALKEY) | $53.11 Million | -10.38% | 4.43x | $27.26 Million |
| Alten SA (ATE) | $336.87 Million | 5.15% | 0.91x | $1.73 Billion |
| Aubay Société Anonyme (AUB) | $35.98 Million | -3.77% | 0.41x | $303.01 Million |
| Union Technologies Informatique Group S.A (FPG) | $4.38 Million | 0.91% | 2.98x | $646.24K |
| Infotel SA (INF) | $92.71 Million | 13.95% | 1.22x | $166.63 Million |
| Cheops Technology France SA (MLCHE) | $24.38 Million | 28.89% | 2.13x | $568.30K |
| Locasystem International SA (MLLOI) | $4.51 Million | 20.14% | 3.79x | $133.42K |